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Introduction {#s1}
============

Heart failure (HF) affects more than 5 million people in the United States. Mechanical Circulatory Support (MCS) therapy is a current temporary strategy for patients with end-stage HF who are not candidates for heart transplantation. Because of the limited availability of donor organs and the approval of MCS for long term (destination) therapy, the use of MCS therapy has grown rapidly over the last 10 years. MCS therapy is considered in patients who are no longer responsive to medical treatment, patients that are not candidates for heart transplantation (as destination or lifetime therapy), patients who are awaiting a heart transplant and/or are becoming too sick due to progressive heart failure, and also in patients with HF in whom myocardial function is expected to return to normal in a short period of time (as a bridge to recovery) [@pone.0115097-Kirklin1]. Outcomes after MCS therapy have significantly improved, yet 10--20% of patients die during the first year post MCS-implantation, usually from sepsis and Multi Organ Dysfunction Syndrome (MOD) [@pone.0115097-Kirklin2]. MOD is linked to an altered immune response induced by the device and the surgical procedure, and is influenced by the preexisting HF [@pone.0115097-Barnes1] [@pone.0115097-Yndestad1] [@pone.0115097-Shahzad1]. Multiple abnormal immune functions describe the critically ill patient: aberrant systemic inflammatory response syndrome (SIRS), altered production of antibodies, abnormal lymphocyte response regulation, release of chemical mediators including cytokines, nitric oxide, endothelin, and prostaglandins [@pone.0115097-Deng1] [@pone.0115097-Redmond1] [@pone.0115097-Redmond2].

Risk prediction tools are commonly used in clinical practice to estimate outcomes. Among them is the Sequential Organ Failure Assessment (SOFA) score, which is useful to predict MOD following MCS therapy. Mortality and length of stay in the ICU and the hospital can be estimated by cross-sectional values of initial score or highest score as well as temporal changes in the SOFA score. Survival is limited for MCS patients with MOD who have high SOFA scores [@pone.0115097-Vincent1]. Early recognition of MOD has important implications in diagnosis, treatment and risk stratification of patients with AdHF undergoing high risk cardiovascular interventions such as MCS, high risk cardiac revascularization, or valve replacement.

However, the SOFA score as well as all other currently available risk scoring tools for MOD ICU patients do not incorporate parameters of immune function, i.e. indicators of the inflammatory response, even though MOD is linked to an exaggerated leukocyte-mediated SIRS. Therefore, we propose a comprehensive evaluation of the immune response associated with MCS implantation and states of multiorgan injury. After completion of the human genome project, global (whole transcriptome) methods of gene expression profiling (GEP) of various tissues and blood cell types have become available for genome-wide evaluation of clinical phenotypes that can now be used to improve clinical evaluation in multiple disease settings. [@pone.0115097-Xie1] [@pone.0115097-Munch1] [@pone.0115097-Cine1] [@pone.0115097-Ma1] [@pone.0115097-Mehra1] [@pone.0115097-Erickson1]. We have previously developed a PBMC GEP test to rule out heart transplant rejection [@pone.0115097-Shahzad2], implemented the test clinically, showed its clinical utility [@pone.0115097-Pham1] and showed its potential to predict clinical events after heart transplantation [@pone.0115097-Deng2], and demonstrated the feasibility of PBMC whole transcriptome GEP in AdHF-patients undergoing MCS-implantation [@pone.0115097-Sinha1]. In this setting, evaluation of the information contained in the PBMC transcriptome may provide a promising solution to this important missing point in the assessment of the critically ill patient.

In the ICU-setting, there are specific challenges to overcome in the development of novel genomic diagnostics. First, several methodological challenges apply to PBMC GEP, which may interfere with reproducibility through the addition of systematic bias when used in the setting of multicenter studies [@pone.0115097-Deng1] [@pone.0115097-Yentis1] [@pone.0115097-Cadeiras1] [@pone.0115097-Cabr1] [@pone.0115097-Dobbin1] [@pone.0115097-Shahzad2] [@pone.0115097-Jison1] [@pone.0115097-Burczynski1]. Second, when approaching the evaluation of critically ill patients, the amount of blood that is obtained may add a complication to the process of recovery. PBMC processing for leukocyte isolation requires 8 ml of blood while WB methods require only 2.5 ml. These patients require multiple blood draws and efforts to minimize loss that is considered in the best interest of the patients. Third, these patients are exposed to blood transfusion, medications, and different degrees of oxygen saturation and fluid loading which could potentially cause error in the results. **(** [**Fig. 1**](#pone-0115097-g001){ref-type="fig"} **)**.

![Variability of methodologies in the processing of gene expression in WB and PBMC.](pone.0115097.g001){#pone-0115097-g001}

It is known that there is a significant overlap between WB and PBMC gene expression [@pone.0115097-Joehanes1]. A study by Whitney et al (2003) found that the proportions of the variety of cell types in peripheral blood can affect the GEP of a patient and that these proportions can rapidly change after an inflammatory response [@pone.0115097-Whitney1]. Debey et al (2004) compared the effect of different isolation techniques in gene expression experiments and found that PBMC analysis yields a more sensitive diagnosis as compared to WB [@pone.0115097-Debey1]. However, Freezor et al (2004) and Palmer et al (2006) discovered that the process was laborious and could affect the GEP [@pone.0115097-Feezor1] [@pone.0115097-Palmer1]. Most recently, Min et al (2012) evaluated the variability of GEP in human blood and lymphoblastoid cell lines. They showed a significant overlap in the gene expression profiles between WB and PBMC [@pone.0115097-Min1].

An important aspect concerning the applicability of new techniques that can be rapidly translated into clinical practice involves its feasibility, reproducibility, cost effectiveness, and ease of implementation, and application. For practical and methodological reasons, such studies are usually performed using purified PBMC samples. However, use of PBMC is labor-intensive and requires several methodological steps that must be strictly followed [@pone.0115097-Joehanes1] [@pone.0115097-Palmer1] [@pone.0115097-Yentis1]. As an alternative, easy-to-use WB gene expression methods have been developed for clinical applications [@pone.0115097-Rainen1]. While comparisons have already been done for gene expression of PBMC and WB supporting the use of both methodologies, it is not known whether the same principles can be applied to critically ill patients undergoing complex surgical procedures [@pone.0115097-DebeyPascher1]. These patients are usually exposed to multiple factors such as repeat blood transfusions, hemodilution, stressors and drugs which could interfere with the applicability of WB gene expression methodologies to this specific population.

Therefore, we hypothesize that mRNA profile of WB from patients with MCS can be used as a surrogate for mRNA profile of PBMC of patients with MCS to identify transcriptome fingerprints for biomarker discovery in various degrees of MOD [@pone.0115097-Rainen1], [@pone.0115097-Raghavachari1], [@pone.0115097-Li1].

Methods {#s2}
=======

Ethics statement {#s2a}
----------------

This study was approved by the Columbia University Office of Human Research Protection Program IRB \# 2206 and all patients signed an informed consent.

Patients {#s2b}
--------

We collected blood samples from 31 consecutive HF patients (57±15 years old) undergoing cardiothoracic surgery (n = 29 MCS, n = 1 coronary artery bypass surgery (CABG) + aortic valve replacement (AVR), n = 1 transcatheter aortic valve replacement (TAVR) and 7 healthy age-matched controls). Samples were obtained between March 2010 and May 2011 at a single institution. PBMC was available for 30 patients and 7 controls, and WB was available for 31 patients and 3 controls. Main characteristics of the study samples are summarized in [**Table 1**](#pone-0115097-t001){ref-type="table"}.

10.1371/journal.pone.0115097.t001

###### Characteristics of the patients.

![](pone.0115097.t001){#pone-0115097-t001-1}

                       Age               Days             SOFA         Gender
  ------------- ------------------ ---------------- ---------------- ----------
  **Control**     52(44.5:55.25)                         0(0:0)       5(62.5)
  **Low**          64(53:70.5)      12.5(18.75:8)       4(4:2.5)      13(92.9)
  **Medium**     60.5(47.5:66.75)     7(9.75:7)       7(8.75:5.25)     5(50)
  **High**       60.5(56.5:65.25)   8.5(20.25:4.5)   16.5(19:13.75)   3(37.5)

Calculations are based on all subjects participating in the study. There were 31 WB samples and 30 PBMC samples from patients and 7 and 3 PBMC and whole blood controls respectively.

Samples were collected at a single time-point postoperatively at a median of 8 days after device implantation (25--75% IQR 7 -- 14 days). The variability of the day 8 sampling time point was dictated by the clinical circumstances. To assess for MOD, we utilized the SOFA score. The SOFA score is a simple, validated, and widely accepted tool that can be easily obtained at a patient\'s bedside and is used to assess patient\'s disease severity and predict survival in the critical care unit [@pone.0115097-Vincent2]. This score has been applied to different study populations including patients with MCS [@pone.0115097-Shahzad3]. SOFA is an integer score that assigns a numerical variable to each of 6 major organ systems to quantify the severity of organ failure. Values range between 0 and 4. Each system\'s value is summed into a single SOFA score. Therefore the sum score ranges between 0 to 24 and correlates with the severity of MOD and clinical outcomes. Following our previous studies [@pone.0115097-Deng2], [@pone.0115097-Pham1], [@pone.0115097-Sinha1], [@pone.0115097-Starling1], we divided the population into SOFA score risk subgroups which were defined as low (≤ 4 points), intermediate (5--11), and high (≥ 12). SOFA score was computed for each patient at the time that gene expression samples were obtained.

Sample collection and RNA isolation {#s2c}
-----------------------------------

Blood was drawn and collected into PaxGene tubes (Becton Dickinson, Franklin Lakes, NJ) for the WB mRNA gene expression analysis or into a CPT tube (Becton Dickinson, Franklin Lakes, NJ) for PBMC cell isolation. For the WB samples, 2.5ml of blood were collected using PaxGene tubes. Samples were incubated at room temperature for 2 hours for RNA stabilization and then stored at −80°C. RNA was extracted from WB using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) according to the manufacturer\'s protocol which includes a globin reduction step. Briefly, samples were removed from −80°C and incubated at room temperature for 2 hours. Following lysis, the tubes were centrifuged for 10 min at 5,000×g, the supernatant was discarded and 500µL of RNase-free water was added to the pellet. Subsequently, the tubes were vortexed thoroughly to re-suspend the pellet, centrifuged for 10 min at 5000×g and the entire supernatant was discarded. The pellet was re-suspended in 360µL of buffer BR1 by vortexing and further purification of RNA was done following the manufacturer\'s protocol with on-column DNase digestion.

For the PBMC samples, mononuclear cells were isolated from 8 ml of blood collected by Vacutainer cell preparation tubes (CPT) with sodium citrate (Becton Dickinson, Franklin Lakes, NJ), resuspended in RNeasy Lysis Buffer (RLT, Qiagen, Valencia, CA) within 2 hours of phlebotomy. Total RNA was isolated from each sample (RNeasy, Qiagen, Valencia, CA). Quality of the purified RNA was verified on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA); RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).

Microarray data processing and analysis {#s2d}
---------------------------------------

After RNA extraction, quantification and quality assessment, total mRNA was amplified and hybridized on the Illumina single color Human BeadChip HT12 v4 whole genome expression array. Each array targets more than 47,000 probes derived from the National Center for Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 (November 7, 2009) and other sources. All samples were processed in a single core facility. After hybridization and microarray chip processing, feature extraction was carried out in the Illumina Beadarray platform (Illumina, San Diego, CA). Data was then subjected to quantile normalization using GenomeStudio (Illumina, San Diego, CA) and normalized expression files for PBMC and WB were used hereafter for comparison.

Filtering was done against background and only those probes having more than 20% variation in the gene expression were retained. Probes mapping to the same gene transcript were not averaged. Data was then transferred to GeneSpring GX 12 (Agilent, Palo Alto, CA). Sample data was normalized using the Quantile normalization method and quality control carried out as implemented in GeneSpring [@pone.0115097-Genespring1]. Given that the starting dataset showed a significant amount of noise in the signal for the WB samples, data was further assessed for the coefficient of variation for each entity within risk groups so only those with a coefficient lower than 0.75 in at least one group were kept for subsequent analysis. This criterion was employed to reduce the intra-group variability, thereby selecting the most reliable entities for potential biomarker candidates.

Quantitative Real-time Polymerase Chain Reaction (RT-qPCR) and Validation {#s2e}
-------------------------------------------------------------------------

Microarray data were validated by Quantitative PCR on PBMC and WB obtained from an independent set of samples. Total RNA from PBMC cells were purified using RNeasy Mini Kit (Qiagen, Valencia, CA) and total RNA from WB cells were purified using the MagNA pure Compact System (Roche, Pleasanton, CA). CDNA was synthesized with iScript supermix for RT-qPCR (BioRad, Hercules, CA). RT-qPCR analysis was carried out with iTaq SYBR green supermix (BioRad, Hercules, CA) on the 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA). 18S rRNA levels were used as an internal control for real-time PCR. Sequences of the primer pairs used were as follows: 18S rRNA, 5′-GTAACCCGTTGAACCCATT-3′ and 5′-CCATCCAATCGGTAGTAGCG-3′; IL11RA, 5′-ACTTCCTGCTCAAGTTCCGT-3′ and 5′-GGCACTGACTCGTACAGCAT-3′; IL2RB, 5′-TTCTAGCGTCAGTGCTGGAG-3′ and 5′-CCTCAGAGATCCCAAAGGAA-3′; TRAF3IP3, 5′- GAGGCTCTGAAGGAGGACTG-3′ and 5′- TATCTGCTCCCTGCAGTTTG-3′; LAT2, 5′- CTACCCACCTGTCACCTCCT-3′ and 5′- CTGTTGGCACCATCAGAATC-3′; CCL5, 5′- AAGGAAGTCAGCATGCCTCT-3′ and 5′- TTTGCCAGTAAGCTCCTGTG-3′; GNLY, 5′-TTCTAGCGTCAGTGCTGGAG-3′ and 5′- ATGCCTTTCACACCCTGTTT-3′; MAP4K1, 5′- AAGATCCAGGACACCAAAGG-3′ and 5′- CTGGTACCACTGAAGCAGGA-3′; ABLIM1, 5′- GTGCAGTTCCCATGAGTCAC-3′ and 5′- GGACAATGGTTTCCTCTGCT-3′; CD96, 5′- AACACCATGGCTGTCACACT-3′ and 5′- AGGCTCGATGGTTCTCAACT-3′; GRB10, 5′- GCAGCCAGTCAGTCTTTCAA-3′ and 5′- GCAGCCAGTCAGTCTTTCAA-3′.

Statistical analysis of gene expression {#s2f}
---------------------------------------

Normalized gene expression samples of normal controls were used as the reference against which samples from patients with low, medium, and high SOFA scores were compared. Statistical comparison was done by the Kruskal-Wallis analysis of variance method and corrected for multiple hypotheses testing using the Benjamini-Hochberg method. Genes that satisfied the significance criteria of less than 5% false discovery rate (FDR) were further analyzed for the enrichment of gene ontology (GO) and subjected to pathway analysis. For the GO analysis, we used High-Throughput GoMiner (HTGM) [@pone.0115097-Zeeberg1] (<http://discover.nci.nih.gov/>) to analyze the enrichment of GO categories by up- and down-regulated genes for both WB and PBMC [@pone.0115097-Harris1]. HTGM analyzes data from all microarrays in a study, provides diagnostics for data interpretation, and allows visualization in the form of clustered heat maps [@pone.0115097-Weinstein1]. Normally, the input to HTGM consists of a total-genes file (representing the entire Microarray or a randomly generated whole genome seed) and a changed-genes file (representing the genes with altered expression) relevant to the study purpose. The output generated by HTGM includes a summary of the results, a matrix whose rows are categories and whose columns are names of changed gene for hierarchical clustering of experiments and categories, and a statistical summary for each category including one-sided Fisher exact p-value and an FDR. Hierarchical clustering of enriched categories and changed genes allows determining which categories achieved statistical significance by virtue of containing essentially the same set of changed genes. For pathway analysis, we used the algorithm incorporated in Genespring, testing for differentially expressed genomic pathways based on the available repositories including Biopax, Wiki, and Reactome. A pathway list was obtained based on Entrez Gene ID and UniGene ID.

To assess the performance of PBMC and WB for biomarker development, we examined the accuracy of predicting the high-risk SOFA group subjects across data sets using the Support Vector Machine (SVM) Class Prediction module in GeneSpring GX 12 (Agilent, Palo Alto, CA), we trained linear kernel SVMs on the PBMC and WB gene datasets defined by the significance criteria described above, as well as the gene set defined by the intersection of these two sets and evaluated the misclassification rates between SOFA groups when each of these trained SVMs were applied to either dataset in its entirety.

Results {#s3}
=======

PBMC versus WB Differential Gene Expression (HF versus Controls) {#s3a}
----------------------------------------------------------------

A general workflow of the analysis depicting differential gene expression for both groups is presented in [**Fig. 2**](#pone-0115097-g002){ref-type="fig"}.

![Flowchart of data analysis.](pone.0115097.g002){#pone-0115097-g002}

The work presented here is the comparison between PBMC and WB whole transcriptome GEP and their correlation to the SOFA score. The combined risk groups of all 31 HF patients exhibited 2605 gene transcripts (2305 genes differentially expressed) in the PBMC and 446 (400 genes differentially expressed) in the WB dataset that had at least a 1.5 fold change in their expression level compared to healthy age-matched controls. While substantially more gene transcripts were differentially expressed in the PBMC compared to WB, there was a significant overlap among them with 333 genes (83.2%) shared by WB and PBMC. The direction of gene expression between WB and PBMC was consistent for 229 genes (68.7%) in the low risk compared to the control group, 245 genes (73.5%) in the medium risk group, and 251 genes (75.4%) in the high risk group. A list of the highest differentially expressed genes overlapping in WB and PBMC is provided in [**Table 2**](#pone-0115097-t002){ref-type="table"}. A list of the overlapping genes and their Pearson correlations with the SOFA score, in both WB and PBMC, is included in the [**S2 Table**](#pone.0115097.s002){ref-type="supplementary-material"}. A complete list of genes both overlapping and non-overlapping for each dataset is also provided in the [**S1 Table**](#pone.0115097.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0115097.t002

###### Most relevant representatives of the overlapping up- and down-regulated genes expressed in PBMC and WB between patients after intervention.
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  Gene symbol    Corrected p-value   Low SOFA score   Medium SOFA score   High SOFA score                   
  ------------- ------------------- ---------------- ------------------- ----------------- ------ --------- ------
  DARC                 0.043             −1.320             down              −2.191        down   −3.601    down
  ENO2                 0.007             −1.431             down              −1.735        down   −2.222     up
  WDR45                0.047             1.409               up                1.801         up     1.833     up
  D40LG                0.005             −2.066             down              −2.702        down   −3.653    down
  CD8B                 0.006             −1.563             down              −1.798        down   −2.359    down
  LCK                  0.005             −1.848             down              −2.431        down   −3.232    down
  FCGBP                0.005             −2.514             down              −2.900        down   −4.858    down
  IL2RB                0.005             −2.473             down              −2.879        down   −8.016    down
  CCL5                 0.005             −1.559             down              −1.975        down   −6.794    down
  CD8A                 0.005             −2.182             down              −3.299        down   −8.575    down
  ICAM2                0.018             −1.637             down              −1.606        down   −2.065    down
  CD79B                0.005             −1.642             down              −1.536        down   −3.059    down
  HLA-DQA1             0.009             −1.778             down              −2.170        down   −6.841    down
  CD3G                 0.005             −1.719             down              −2.177        down   −3.780    down
  CD3D                 0.005             −2.027             down              −3.295        down   −7.713    down
  IL32                 0.005             −1.569             down              −2.172        down   −3.799    down
  VSIG4                0.005             1.257               up                1.962         up    10.599     up
  S1PR5                0.005             −2.610             down              −2.857        down   −7.143    down
  CD3D                 0.005             −2.026             down              −3.154        down   −7.734    down
  ITM2A                0.005             −1.913             down              −2.792        down   −5.529    down
  IL1R2                0.011             1.135               up                1.976         up    15.480     up
  KLRD1                0.005             −1.941             down              −2.374        down   −6.028    down
  CD79A                0.005             −1.842             down              −1.809        down   −3.061    down
  CD3E                 0.005             −1.837             down              −2.734        down   −4.568    down
  PTGDS                0.009             −1.752             down              −2.099        down   −3.329    down
  TLR9                 0.045             −1.168             down              −1.240        down   −1.277    down
  GZMB                 0.006             −2.316             down              −2.226        down   −7.583    down
  CX3CR1               0.007             −1.200             down              −1.012        down   −3.954    down
  AHSP                 0.014             23.029              up               28.623         up    64.306     up
  C19orf2              0.016             −1.469             down              −1.476        down   −1.823    down
  TRADD                0.006             −1.453             down              −1.795        down   −2.209    down
  CD96                 0.005             −2.256             down              −2.748        down   −4.935    down
  IL11RA               0.006             −1.783             down              −2.298        down   −3.334    down
  CD8A                 0.006             −2.283             down              −3.234        down   −8.740    down
  BCL2                 0.005             −1.341             down              −1.854        down   −3.008    down
  FCER1A               0.005             −2.269             down              −3.763        down   −10.177   down
  GZMA                 0.006             −2.062             down              −2.194        down   −7.656    down
  IL7R                 0.005             −2.319             down              −3.891        down   −7.479    down
  FAM102A              0.005             −2.212             down              −2.908        down   −4.824    down
  SPOCK2               0.005             −1.935             down              −3.351        down   −5.789    down
  SBK1                 0.005             −2.070             down              −2.698        down   −5.390    down
  CXCR5                0.010             −1.858             down              −2.112        down   −2.693    down
  IL7R                 0.005             −2.418             down              −3.905        down   −8.217    down
  CD247                0.005             −2.436             down              −3.467        down   −9.013    down
  CD2                  0.005             −2.245             down              −3.349        down   −7.121    down
  GPR56                0.006             −2.228             down              −2.612        down   −9.470    down
  GNLY                 0.005             −2.189             down              −2.584        down   −9.530    down
  MYC                  0.022             −1.383             down              −1.770        down   −2.474    down
  GNLY                 0.005             −2.302             down              −2.738        down   −9.103    down
  HP                   0.011             3.279               up                4.755         up     6.795     up
  STAT4                0.005             −2.161             down               3.066        down    5.837    down

PBMC versus WB Biomarker Candidate Gene Discovery {#s3b}
-------------------------------------------------

Expression patterns of the highest differentially expressed genes have been clustered as a heatmap for visualization purposes and provided in [**Fig. 3**](#pone-0115097-g003){ref-type="fig"}.

![Clustered heatmap of the overlapping 333 genes in WB and PBMC shows highly correlated gene expression patterns.](pone.0115097.g003){#pone-0115097-g003}

This shows that patterns of the highest differentially expressed genes have similar profiles for PBMC and WB. For these genes, we used text mining algorithms as implemented in GeneSpring to identify those with the highest connectivity and most likely to have an important role in the inflammation process. These genes included IL11RA, CCLS, GNLY, MAP4K1, LAT2, CD96, GRB10, and IL2RB.

Validation of PBMC and WB differentially regulated genes by RT-qPCR {#s3c}
-------------------------------------------------------------------

To validate the microarray results in this study we used an alternative approach. We performed RT-qPCR to assay the 10 highest ranked genes, ranked first by statistical significance, secondly by correlation between WB and PBMC microarray expression levels, and finally by biological relevance **(** [**Table 3**](#pone-0115097-t003){ref-type="table"} **).**

10.1371/journal.pone.0115097.t003

###### Differentially expressed, highest connected genes sorted by connectivity (n).
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  Gene (Number of Connectivity)                                                                                                                                                                                            Function                                                                                                                                                                    Disease
  ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------
  **IL11RA-** Interleukin 11 Receptor, Alpha                                                                                                            Stromal cell derived cytokine, uses gp130 transducing subunit in their high affinity receptors, members of the hematopoietic cytokine family.                                                                                          Megakaryocytic leukemia
  **IL2RB-** Interleukin 2 Receptor, Beta                                                                                                 T-cell mediated immune response. Intermediate and high affinity forms of IL2RB involved in receptor-mediated endocytosis and transduction of mitogenic signals from IL-2.                                                                Occipital neuralgia, and granulomatous orchitis
  **TRAF3IP3-** TRAF3 Interacting Jun N Terminal Kinase (JNK) Activating Modulator                                                                                               Mediates cell growth through modulating c-Jun N-terminal kinase signal transduction pathway.                                                                                                    Rectum cancer, cerebral cavernous malformations 3.
  **LAT2-** Linker for Activation of T-Cells                                          Encoded protein is phosphorylated by ZAP-70/Syk protein tyrosine kinases following activation of the T-Cell antigen receptor (TCR) signal transduction pathway. Protein then recruits multiplied adaptor proteins and downstream signaling molecules into multi-molecular signals.                 Mitral valve stenosis, and alexia.
  **CCL5-** Chemokine (C-C Motif) Ligand 5                                                     Chemokine superfamily; member of the CC subfamily. Chemoattractant for blood monocytes, memory T helper cells and eosinophils. Causes histamine release from basophils and activates eosinophils. Cytokine is an HIV-suppressive factor produced by CD8+ cells.                       Ulcer of lower limbs, meningoencephalitis.
  **GNLY-** Granulysin                                                                                                                  Saposin-like protein (SAPLIP). Present in cytotoxic granules of cytotoxic T-lymphocytes and NK cells. Has antimicrobial activity against M. Tuberculosis and other organisms.                                                               Folliculitis, and spondylocostal dysostosis.
  **MAP4K1-** Mitogen-Activated Protein Kinase Kinase Kinase                                                                                                                               Protein coding. Gene associated with pancreatic cancer and pancreatitis.                                                                                                                      Pancreatic cancer, and pancreatitis
  **ABLIM1-** Actin binding LIM protein 1                                                                     Encodes a cytoskeletal LIM protein that binds to actin filaments via a domain that is homologous to erythrocyte dematin. LIM domains also function as protein binding interfaces, mediating specific protein-protein interactions.                                  Corneal neovascularization and alcohol dependence
  **CD96-** CD96 Molecule                                                                                                                                    Type-1 membrane protein, immunoglobulin superfamily. Adhesive interactions of T-Cells and NK cells in late stage of immune response.                                                                                       Cat eye syndrome and c-like syndrome
  **GRB10-** Growth factor receptor bound protein 10                                                      Small family of adapter proteins-interact with several receptor tyrosine kinases and signaling molecules. Encodes a growth factor receptor-binding protein that interacts with insulin receptors and insulin-like growth factor receptors.                       Silver-russell syndrome, albright\'s hereditary osteodystrophy.

To perform this validation, we analyzed RT-qPCR of 8 samples taken from across control, low/medium, and high SOFA score groups. Fold changes were calculated against control, averaged in each group by their logarithms, and transformed back. We compared the microarray and RT-qPCR results of expression of 10 genes between the SOFA score sub-groupings within the PBMC and WB groupings **(** [**Fig. 4**](#pone-0115097-g004){ref-type="fig"} **)**.

![RT-qPCR validation of three differentially expressed genes within PBMC and WB subgroups, within SOFA groups.\
Darker colors correspond to higher magnitude of fold change. Fold changes showed similar patterns between all 10 genes, 9 of which are down-regulated, and 1 of which is up-regulated. 7 of 10 genes showed similar patterns between PBMC and WB and also within SOFA score groups according to our microarray and PCR results. 2 of 10 genes (IL11RA and GRB10) show an opposite result in HIGH PCR (PBMC) and low/med array (WB) correspondingly. Only 1 gene, MAP4K1, shows an opposite result between SOFA score groups.](pone.0115097.g004){#pone-0115097-g004}

PBMC versus WB Gene Ontology analysis {#s3d}
-------------------------------------

GO analysis identified 314 terms enriched by 1327 genes. 35 of these terms overlapped between WB and PBMC. GO categories included regulation of the immune response and related pathways including the innate and the adaptive immune responses. Interestingly, there was a pronounced enrichment of innate response GO terms by up-regulated genes and of the adaptive immune response by down-regulated genes as previously described in the setting of critical illness [@pone.0115097-Joehanes1]. Other enriched GO terms were related to programmed cell death and the coagulation cascade, both well known to be involved in the biology of critical illness [@pone.0115097-Draghici1]. The identification of these processes in the context of the known biology supports the validity of our findings as opposed to random enrichment of GO categories. The overall enrichment found in the PBMC dataset compared to WB showed that the majority of genes, while different, were likely involved in similar biological processes. Thus, GO analysis suggests that for both PBMC and WB, expressed genes are involved in inflammation, apoptosis, and stress response related pathways among others. There is a significant difference in the number of GO categories but not in the processes represented by these categories. The lack of a significant enrichment of GO categories or members of a specific gene pathway in the WB dataset could be explained by different power assumptions when starting from a smaller number of genes. However, differences in the direction of gene expression could be explained by multiple mechanisms that reside in the interface between WB composition and PBMC and need to be further investigated. Genes in the overlap dataset include members of pathways such as Apoptosis (BCL2, MAGED1, and TNFRSF10B), Nephrin interactions (FYN), CD28 and CD28 co-stimulation (CD28r), Cell-extracellular matrix interactions (BCL2, LAT2, KLFR1, KLRD1, TRAT1, PTCRA, KLRB1, and ICAM2), Antiviral mechanism mediated by Interferon gamma signaling (IL1R2 and IRAK3), and Lipoprotein metabolism including LDL-mediated lipid transport, and Chylomicron-mediated lipid transport (LPL, VLDL, and TGIHDL). The most relevant GO categories enriched in PBMC and WB are described in [**Table 4**](#pone-0115097-t004){ref-type="table"}.

10.1371/journal.pone.0115097.t004

###### Most relevant representative of GO categories overlapping between PBMC and WB after intervention.
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  GO accession                  GO Term                  FDR    N selection   \% selection   N Total   \% Total
  -------------- ------------------------------------- ------- ------------- -------------- --------- ----------
  GO:0001817       regulation of cytokine production    0.061       37         1.4020462       125      0.747
  GO:0002376             immune system process          0.000       243         9.208034       823      4.921
  GO:0002682      regulation of immune system process   0.000       85          3.220917       257      1.537
  GO:0006915                   apoptosis                0.011       98          3.713528       425      2.541
  GO:0010941           regulation of cell death         0.000       135         5.115574       545      3.259
  GO:0042101            T cell receptor complex         0.000       11         0.41682455      12       0.072
  GO:0045321             leukocyte activation           0.014       51         1.9325502       178      1.064
  GO:0046649             lymphocyte activation          0.006       46         1.7430845       149      0.891

Of particular interest in the heatmap **(** [**Fig. 3**](#pone-0115097-g003){ref-type="fig"} **)** are the areas where multiple GO categories overlap or "cross-talk", suggesting that mechanisms involved for a specific set of genes are common to different biological processes. Those GO terms were related to molecular mechanisms associated with inflammation leading to T-cell activation, activation of cytokine signaling cascades, and regulation of programmed cell death. Other important biological processes identified in the non-overlapping genes included "cross-talking" GO categories involving regulation of peptidase, caspase, and endopeptidase activity. A complete list of overlapping and non-overlapping GO categories is provided in [**S3 Table**](#pone.0115097.s003){ref-type="supplementary-material"}.

PBMC versus WB Pathway analysis {#s3e}
-------------------------------

The total number of differentially expressed pathways associated with up- or down-regulated genes was 26 in the WB dataset and 265 in the PBMC dataset. A total of 137 genes present in the WB pathway enrichment analysis were also included in the list of genes from PBMC pathways (466). The enrichment analysis revealed that 26 pathways were associated with up-regulated genes based on a corrected 2-tailed p-value \<0.05 (5% FDR). Pathways differentially regulated in WB that were common to PBMC included the adaptive immune system. Out of 40 genes listed under the adaptive immune system pathway, 10 genes (25%) in the WB dataset were differentially expressed and 15 genes (37.5%) in the PBMC dataset were differentially expressed (p-values\<0.001). Genes in this pathway including ITK, LAT, LCK, and TRAT1 were found to be up-regulated in both PBMC and WB. Eleven genes were up-regulated in PBMC but down-regulated in WB. The T-Cell receptor signaling pathway showed an enrichment of 30% (7/23 genes, (p =  3.8×10^−09^). Other important pathways included apoptosis, homeostasis, and those associated with HIV infections, CD28 and GPCR signaling. Significantly enriched pathways and corresponding gene expression are listed in [**Table 5**](#pone-0115097-t005){ref-type="table"}.

10.1371/journal.pone.0115097.t005

###### Pathway analysis by overlapping up- and down-regulated genes expressed in PBMC and WB after intervention.
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  Genes which overlap in PBMC and WB                                                                                       
  -------------------------------------------------------------------------- ----------- ------ -------- -------- -------- --------
  Immune System                                                                 BTLA                      TRAT1    TRAT1   
                                                                                 LAT                                       
                                                                                PLCG1                                      
                                                                                PRKCQ                                      
                                                                                ZAP70                                      
  Adaptive Immune System                                                         ITK              BTLA     FYN      FYN      BTLA
                                                                                 LAT             CARD11                     CARD11
                                                                                 LCK                                       
                                                                                TRAT1                                      
  Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell      CD160            CD40LG    KLD1     KLD1    CD40LG
                                                                                CD96                                       
  Costimulation by the CD28 family                                               ITK      LAT                              
  Chemokine receptors bind chemokines                                           CCL5                                       
                                                                                CCL7                                       
                                                                                CXCR6                                      
  HIV Infection                                                                  LCK             CD247     NMT2     NMT2    CD247
  Apoptosis                                                                     BCL2              GZMB    TRADD    TRADD     GZMB
                                                                               MAGED1                     PRKCQ    PRKCQ   
                                                                              TNFRSF10B                                    
  Class A/1 (Rhodopsin-like receptors)                                          CCR7             GPR18     CCL5     CCL5    GPR18
                                                                                CXCR6                      CXR5     CXR5   
                                                                                GPR44                                      
  Hemostasis                                                                     CD2                       FYN      FYN    
                                                                                JAM3                       LAT      LAT    
                                                                               KIFAP3                                      
                                                                                 LCK                                       
                                                                                MAFG                                       
                                                                                PLCG1                                      
  Nef and signal transduction                                                   CD247                                      
                                                                                 FYN                                       
  Network Regulators                                                            CD8A              CD3D     CD3G     CD3G     CD3D
  Signal Transduction                                                           PLCG1                                      
                                                                               SH3KBP1                                     
  GPCR ligand binding                                                           CXCR5             CCL5     CCR7     CCR7     CCL5
                                                                                GPR18                     CXCR6    CXCR6   
                                                                                GPR44                                      
  Signaling by GPCR                                                             CXCR5     CCL5             CCR7     CCR7   
                                                                                CXCR6                                      
                                                                                GPR18                                      
                                                                                GPR44                                      
  Signaling by Interleukins                                                     IL1R2            IL2RB     IL7R     IL7R    IL2RB
                                                                                IRAK3                                      
  Small Molecules                                                                LCK                      PRKCQ    PRKCQ   
                                                                                                          PLCG1    PLCG1   
                                                                                                          SIGIRR   SIGIRR  
  TCR signaling                                                                  LAT                      CARD11   CARD11  
                                                                                PLCQ1                      ITK      ITK    
                                                                                PRKCQ                                      
                                                                                TRAT1                                      
                                                                                ZAP70                                      
  The role of Nef in HIV-1 replication and disease pathogenesis                 CD247             LCK                        LCK
                                                                                 FYN                                       
  Toll Receptor Cascades                                                       SIGIRR                     IRAK3    IRAK3   
                                                                                TLR5                                       
  Peptide ligand-binding receptors                                                        CXR5             CCL5     CCL5   
                                                                                                           CCR7     CCR7   
                                                                                                           CXR6     CXR6   

For the pathway analysis, we found that of the 34 significant genes that overlapped between PBMC and WB pathway groups, 26 had concordantly regulated patterns in both groups. The other 8 genes showed an opposite expression in PBMC and WB datasets. Results observed in the WB samples were similar in several aspects to those in the PBMC datasets, supporting the role of these genes as potential biomarkers for early diagnosis and monitoring of MOD. Variations in the direction of gene expression suggest that perturbations in multiple signaling and cellular mechanisms occur in a comparable way in PBMC as in WB.

Performance of classification using PBMC and WB {#s3f}
-----------------------------------------------

We employed a support vector machine (SVM) to examine the accuracy of predicting the high-risk SOFA group subjects across data sets. Misclassification rates between the SOFA groups, when each of these trained SVMs was applied to either dataset, are shown as confusion matrices in [**Table 6**](#pone-0115097-t006){ref-type="table"}.

10.1371/journal.pone.0115097.t006

###### SVM Misclassification Tables.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- --------- --------- ----------
  **A:** WB trained SVM applied to PBMC accurately predicts MED and HIGH, with confusion of CTRL and LOW.                                                                                                                                                                                              
                                                                                                                                                                                                                                                                         **CTRL**   **LOW**   **MED**   **HIGH**
  **CTRL**                                                                                                                                                                                                                                                                  1          6         0         0
  **LOW**                                                                                                                                                                                                                                                                   2          5         1         0
  **MED**                                                                                                                                                                                                                                                                   0          0        14         0
  **HIGH**                                                                                                                                                                                                                                                                  0          0         0         8
  **B:** PBMC trained SVM applied to WB is not good as expected, because the SVM was trained on PBMC genes that were not found to be significant in WB.                                                                                                                                                
  **CTRL**                                                                                                                                                                                                                                                                  2          0         0         1
  **LOW**                                                                                                                                                                                                                                                                   0          8         0         0
  **MED**                                                                                                                                                                                                                                                                   3          0        10         1
  **HIGH**                                                                                                                                                                                                                                                                  4          0         1         3
  **C:** Overlapping PBMC SVM trained applied to PBMC (This means that the subset of genes in PBMC that are the overlapping genes with WB are sufficient in reproducing the prediction found by the entire set)                                                                                        
  **CTRL**                                                                                                                                                                                                                                                                  7          0         0         0
  **LOW**                                                                                                                                                                                                                                                                   0          8         0         0
  **MED**                                                                                                                                                                                                                                                                   0          0        14         0
  **HIGH**                                                                                                                                                                                                                                                                  0          0         0         8
  **D:** Overlapping PBMC SVM trained applied to WB. (This shows that the prediction of the MED and HIGH risk groups based on training the SVM on the Overlap PBMC gene set is transferrable to the WB dataset. This is the consistency argument we are looking for.)                                  
  **CTRL**                                                                                                                                                                                                                                                                  3          0         0         0
  **LOW**                                                                                                                                                                                                                                                                   3          3         0         2
  **MED**                                                                                                                                                                                                                                                                   0          0        14         0
  **HIGH**                                                                                                                                                                                                                                                                  0          0         1         7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- --------- --------- ----------

We found that the SVM trained on the WB genes were accurate in predicting the medium and high risk SOFA subjects in the PBMC dataset (a), and the overlapping PBMC genes were accurate in predicting the medium and high risk SOFA subjects in the WB dataset (d). Also, training on only the overlapping PBMC genes was sufficient to accurately predict all patients in the PBMC group (c). However, training on all PBMC genes was not useful in predicting in the WB group because the SVM relies heavily on information about genes that were not significant in the WB dataset (b).

Discussion {#s4}
==========

In this paper, we show that WB can be used as a surrogate of PBMC expression in a set of critically ill patients who underwent AdHF cardiac surgery. We validate this result with independent set of samples using RT-qPCR. Our results indicate that the direction of change in gene expression profiles of individuals with MOD as compared to controls is similar when determined from PBMC versus WB. In each of the low, medium and high risk SOFA score patients; there was consistency in the direction of gene expression changes. The main enriched terms by GO analysis included those involved in the inflammatory response, apoptosis, and other stress response related pathways. The data revealed that there were 35 significant GO categories and 26 pathways overlapping between PBMC and WB. Additionally, class prediction using machine learning tools demonstrate that the subset of significant genes shared by both PBMC and WB are sufficient to train a predictor separating the SOFA groups.

Overall, multiple explanations can be postulated to support our findings. First, the differences between PBMC and WB could be secondary to lower signal-to-noise ratios in WB, leading to a higher number of false positive rates when tested with multiple comparisons. Thus, a way to reduce the ratio of true positives to true negatives required an additional step in filtering those transcripts with high intraphenotypic variability that would otherwise be removed by multiple hypothesis testing. As a positive consequence, only those transcripts that are more stable across phenotypes are retained for the analysis, providing a more reproducible signal with lower enrichment but higher correlated findings in the PBMC dataset.

Second, while most relevant changes in gene expression are captured by both methods, variability seems larger in the WB leading to many transcripts not being significant when tested with multiple hypotheses.

Third, the globin mRNA depletion method used in the PAXgene stabilized RNA leads to variable changes in gene expression based on different concentrations of WB and content of globin transcripts. Globin reduction protocols [@pone.0115097-XX1] [@pone.0115097-XX2] [@pone.0115097-GlobinRNAReductioninBloodSamples1] [@pone.0115097-Rainen2] [@pone.0115097-Li1] have been used to improve microarray data quality by reducing data variability with increased detection rate of expressed genes and improved overlap with the expression signatures of isolated PBMC preparations.

Fourth, the differential composition of cell populations in PBMC and WB might account for differences in GEP patterns. While PBMC seems to directly identify changes in a well-defined immunological set of cells, such an assumption does not apply to WB. In WB, more diverse cell populations including neutrophils, eosinophils, platelets and reticulocytes among other constituents in the preparations, reduce the specific cell population of the study. While they have the potential to be used as biomarkers with the goal of classifying phenotypes, the biological meaning of the results is highly questionable when proposing mechanistic explanations. A comparative analysis revealed that nearly 2,000 genes with at least a 2-fold average difference in expression between WB and PBMCs could reflect the difference in cellular composition [@pone.0115097-Whitney1] [@pone.0115097-Min1]. Gene expression associated with WB displays a more pronounced pattern of up-regulation **(** [**Table 5**](#pone-0115097-t005){ref-type="table"}). Theoretically, in both PBMC and WB sampling, analysis is possible using microfluidics-based flow cytometry-guided cell sorting followed by subpopulation-specific GEP [@pone.0115097-Kotz1] [@pone.0115097-Rosenbach1]. However, the intention of our approach, in creating a clinically feasible protocol, is to use the integrated mixed PBMC population in the original PBMC protocol and compare it with the WB-approach.

Fifth, the observed differences could also be explained by different RNA processing methods that have an effect on gene expression profile in WB and PBMC samples.

Sixth, the results in RT-qPCR showed non-significant differences between the 10 genes when compared to the microarray results.

Lastly, we have obtained high classification rates using both PBMC and WB. Although PBMC provided more accurate results, classification rates for the moderate and high risk groups were well discriminated by WB which provides significant advantages from a methodological and clinical implementation perspectives.

Limitations {#s4a}
-----------

Our findings should be interpreted in consideration of several study limitations including: 1) limited sample size, 2) lack of power to assess gender specific variation, 3) variation in the time points of collection dictated by clinical setting, 4) use of the SOFA score which has not been specifically developed for the MCS population, and 5) use of cross-sectional single time-point evaluations.

Conclusions {#s5}
===========

We conducted a study to evaluate the comparative usefulness of WB and PBMC transcriptome analysis in critically ill patients undergoing a complex and high risk cardiovascular intervention such as MCS therapy. We found that although there was a significant difference in sensitivity, molecular fingerprints of WB and PBMC had a good overlap and concordance in their gene expression with common pathways and mechanisms represented by these genes.

WB as well as PBMC is useful to delineate the inflammatory response associated with MOD after MCS. While PBMC classification outperformed WB, technical refinement and development of larger, prospective studies are warranted to further develop WB biomarkers in critical care settings.

Advantages of PBMC testing include better biological inquiry at the cost of methodological challenges with difficult implementation in the real world clinical setting. While WB potentially carries a reduced value in classification performance and reflection of actual biology, it has the advantage of easier implementation, requires a smaller volume, and is more resistant to operational variation. Even though the critical care setting is associated with many complex interventions, these do not appear to interfere with the ability of using WB biomarkers to identify high risk patients.
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